BIOLARGO, INC.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOLARGO, INC. | ||
| Date: March 4, 2026 | By: | /s/ Dennis P. Calvert |
|---|---|---|
| Dennis P. Calvert President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Dennis P. Calvert and Joseph L. Provenzano, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the date indicated:
| Name | Title | Date |
|---|---|---|
| /s/ Dennis P. Calvert | Chairman of the Board, Chief | March 4, 2026 |
| Dennis P. Calvert | Executive Officer and President | |
| /s/ Charles K. Dargan II | Chief Financial Officer | March 4, 2026 |
| Charles K. Dargan II | (principal financial officer and principal accounting officer) | |
| /s/ Kenneth R. Code | Chief Science Officer and Director | March 4, 2026 |
| Kenneth R. Code | ||
| /s/ Joseph L. Provenzano | Executive Vice President, Corporate | March 4, 2026 |
| Joseph L. Provenzano | Secretary and Director | |
| /s/ Jack B. Strommen | Director | March 4, 2026 |
| Jack B. Strommen | ||
| /s/ Dennis E. Marshall | Director | March 4, 2026 |
| Dennis E. Marshall | ||
| /s/ Linda Park | Director | March 4, 2026 |
| Linda Park | ||
| /s/Christina Bray | Director | March 4, 2026 |
| Christina Bray | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.